Apr 30 |
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
|
Apr 29 |
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
|
Apr 15 |
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
|
Apr 8 |
TFF Pharmaceuticals files to sell common stock, warrants
|